Table 3 Bevacizumab-containing combination therapies in HNSCC

 Pemetrexed + bevacizumab

Single arm, Phase II

n = 47

Median TTP 5 months

Argiris, 2011 [25]

 Chemotherapy +/− bevacizumab (chemotherapy was investigator’s choice:

cisplatin+ 5-FU, cisplatin+docetaxel, carboplatin+ 5-FU, or carboplatin+ docetaxel)

Randomized, Phase III

n = 403

Median overall survival 12.6 months with bevacizumab and 11 months without bevacizumab (p = 0.13)

Argiris, 2019 [26]

 RT + docetaxel + bevacizumab

Single arm, Phase II

n = 30

3-year PFS 62%

Yao, 2015 [27]

 RT + cisplatin + bevacizumab

Single arm, Phase II

n = 42

2-year PFS 76%

Fury, 2012 [28]

 RT + 5-FU, hydroxyurea + bevacizumab

Randomized, Phase II

n = 26

2-year OS 58% with bevacizumab and 89% without bevacizumab

Salama, 2011 [29]

 Cetuximab + bevacizumab

Single arm, Phase II

n = 46

RR 16%

Argiris, 2013 [30]

 Erlotinib + bevacizumab

Single arm, Phase I/II

Phase I n = 10

Phase II n = 48

Median PFS 4.1 months

Cohen, 2009 [31]

 RT + pemetrexed+ cetuximab +/− bevacizumab

Randomized, Phase II

n = 78

2-year PFS 75% with bevacizumab and 79% without bevacizumab

Argiris, 2016 [32]

 RT + cisplatin+ cetuximab + bevacizumab

Single arm, Phase II

n = 30

2-year PFS 88.5%

Fury, 2016 [33]

 Paclitaxel+ carboplatin+ 5-FU + bevacizumab, followed by RT + paclitaxel + erlotinib + bevacizumab

Single arm, Phase II

n = 60

3-year PFS 71%

Hainsworth, 2011 [34]